OOIR: Observatory of International Research

Papers

(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis	121
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis	65
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study	36
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome	35
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI	27
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data	26
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients	26
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment	26
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients	24
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review	23
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)	22
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids	22
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study	20
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs	20
Calcineurin inhibitors in systemic sclerosis – a systematic literature review	19
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry	19
Health disparities in rheumatoid arthritis	17
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors	17
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials	17